Who is sponsoring NCT04232241?

NCT04232241 is sponsored by Universitätsklinikum Hamburg-Eppendorf.

What drugs are being tested in NCT04232241?

Interventions in NCT04232241: Allogeneic Stem Cell Transplantation.

What condition does NCT04232241 study?

NCT04232241 studies Acute Myeloid Leukemia in Remission, Acute Lymphoblastic Leukemia in Remission, Myelodysplastic Syndromes.

Is NCT04232241 still recruiting?

NCT04232241 is currently active, enrolled. Last updated 22 April 2025.

Last reviewed 2025-04-22 · How we verify

NCT04232241

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia

Active, enrolled Phase 2 Last updated 22 April 2025

What this trial tests

Phase 2 trial testing Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia in Remission in 167 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

14 November 2019

Primary endpoint
22 November 2026

26 November 2026

Quick facts

Lead sponsor	Universitätsklinikum Hamburg-Eppendorf
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	167
Start date	14 November 2019
Primary completion	22 November 2026
Estimated completion	26 November 2026
Sites	24 locations across Italy, Finland, Russia, Austria, Germany, Spain, Czechia

Drugs / interventions tested

Allogeneic Stem Cell Transplantation — full drug profile →

Conditions studied

Acute Myeloid Leukemia in Remission — all drugs for Acute Myeloid Leukemia in Remission →
Acute Lymphoblastic Leukemia in Remission — all drugs for Acute Lymphoblastic Leukemia in Remission →
Myelodysplastic Syndromes — all drugs for Myelodysplastic Syndromes →

Sponsor

Universitätsklinikum Hamburg-Eppendorf — full company profile →

Who can join

Adults 18 to 70, any sex, with Acute Myeloid Leukemia in Remission or Acute Lymphoblastic Leukemia in Remission. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Primary objective of this open label, two-arm, multicenter, multinational, randomized trial is to compare anti-leukemic activity of allogeneic stem cell transplantation for patients with acute leukemia in complete remission between a 10/10 HLA matched unrelated donor and a haploidentical donor. The hypothesis: Haploidentical stem cell transplantation with post cyclophosphamide induces a stronger anti-leukemic activity in comparison to 10/10 HLA matched unrelated donor and reduces the risk of relapse at 2 years after stem cell transplantation by 10%.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT.
Sanz J, Galimard JE, Labopin M, Afanasyev B, et al · · 2021 · cited 39× · PMID 34049582 · DOI 10.1186/s13045-021-01094-2
Haploidentical Stem Cell Transplantation for Acute Myeloid Leukemia: Current Therapies, Challenges and Future Prospective.
Chang YJ, Zhao XY, Huang XJ. · · 2021 · cited 15× · PMID 34778077 · DOI 10.3389/fonc.2021.758512
Effective Immunosurveillance After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia.
Kunadt D, Stölzel F. · · 2021 · cited 3× · PMID 34594134 · DOI 10.2147/cmar.s261721
The EHA Research Roadmap: Hematopoietic Stem Cells and Allotransplantation.
Fibbe W, Bernardi R, Charbord P, Krause D, et al · · 2022 · cited 1× · PMID 35509429 · DOI 10.1097/hs9.0000000000000714

Verify or expand the search:

Other trials of Allogeneic Stem Cell Transplantation

Trials testing the same drug.

NCT07297173 — Phase 1 Study of Chemotherapy Plus HLA-mismatched GPBMC Infusion Bridging to Allo-HSCT for R/R Leukemia · Phase 1 · recruiting
NCT06345495 — High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly · Phase 2 · recruiting
NCT02410551 — Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN) · Phase 2 · terminated
NCT02059239 — Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma · Phase 1, PHASE2 · completed
NCT02098512 — Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin L · Phase 1, PHASE2 · unknown

Other recruiting trials for Acute Myeloid Leukemia in Remission

Currently open trials in the same condition.

NCT06440135 — Ziftomenib Maintenance Post Allo-HCT · Phase 1 · recruiting
NCT06462365 — Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT) · Phase 1 · recruiting
NCT05236764 — Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion · NA · active not recruiting
NCT05917405 — Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT · Phase 2 · recruiting
NCT05224661 — Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events · active not recruiting

Other Universitätsklinikum Hamburg-Eppendorf trials

Trials by the same sponsor.

NCT07443384 — Complications Associated With Radiofrequency Microneedling in Dermatology: a Delphi Consensus · not yet recruiting
NCT07385092 — Continuous Vital Sign Monitoring Versus Routine Spot-checks in Patients After Non-cardiac Surgery · NA · recruiting
NCT07009522 — Hamburg Emotion Awareness and Regulation Group Training for Autistic Adolescents (HEART) · EARLY_PHASE1 · not yet recruiting
NCT07115394 — EEG Measurements to Capture DBS-induced Electric Potentials · recruiting
NCT06955884 — Patient Experience of Transoral Versus Transnasal Awake Tracheal Intubation · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04232241 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Universitätsklinikum Hamburg-Eppendorf
Last refreshed: 22 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04232241.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing